GENETICS & IVF INSTITUTE v. Kappos

801 F. Supp. 2d 497, 100 U.S.P.Q. 2d (BNA) 1114, 2011 U.S. Dist. LEXIS 79287, 2011 WL 2971982
CourtDistrict Court, E.D. Virginia
DecidedJuly 21, 2011
Docket1:10cv996 JCC/TRJ
StatusPublished

This text of 801 F. Supp. 2d 497 (GENETICS & IVF INSTITUTE v. Kappos) is published on Counsel Stack Legal Research, covering District Court, E.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
GENETICS & IVF INSTITUTE v. Kappos, 801 F. Supp. 2d 497, 100 U.S.P.Q. 2d (BNA) 1114, 2011 U.S. Dist. LEXIS 79287, 2011 WL 2971982 (E.D. Va. 2011).

Opinion

MEMORANDUM OPINION

JAMES C. CACHERIS, District Judge.

This matter is before the Court on the parties’ cross-motions for summary judgment. For the following reasons, the Court will deny Plaintiffs motion, [Dkt. 13], and will grant Defendants’ motion, [Dkt. 15].

I. Background

A. The Parties and the Case

Plaintiff Genetics & IVF Institute (“Plaintiff’ or “GIVF”) brings this action against defendants the United States Patent and Trademark Office (the “USPTO”) and David Kappos, in his official capacity as Under Secretary of Commerce for Intellectual Property and Director of the USPTO (together with the USPTO, “Defendants”). Under the Administrative *500 Procedure Act, 5 U.S.C. §§ 551-706 (the “APA”), Plaintiff seeks to set aside the denial of an application made under the Drug Price Competition and Patent Term Restoration Act, popularly known as the “Hateh-Waxman Act,” Pub.L. No. 98-417, 98 Stat. 1585 (Sept. 24,1984), to extend the term of a U.S. patent, as further described below. (Complaint (“Compl.”) [Dkt. 1] ¶1.)

B. Overview of Relevant Patent Law

Under the Patent Act, 35 U.S.C. § 100 et seq. (the “Patent Act”), a United States patent expires after a certain term, generally 20 years from the date on which the patent application was filed. See 35 U.S.C. § 154(a)(2). For patents claiming certain drug and medical devices, some or all of the patent term may be consumed by the (often lengthy) Food and Drug Administration (“FDA”) approval process for products utilizing that patent. See 35 U.S.C. § 156; 21 U.S.C. § 355(a).

Recognizing this, the Hatch-Waxman Act provides patent holders with “interim” extensions for patents utilized by products that remain under FDA review when the relevant patent term is set to expire. These extensions, however, are not automatic. The first time a patent holder seeks an interim patent term extension (an “Extension”), the relevant statute, 35 U.S.C. § 156(d)(5)(A), provides that the holder must file an application with the USPTO “during the period beginning [six] months, and ending 15 days, before [the patent term] is due to expire.” Then, “[i]f the [USPTO] Director determines that, except for permission to market or use the product commercially, the patent would be eligible for an extension of the patent term under this section ... [the Director] shall issue to the applicant a certificate of interim extension” for a maximum length of one year. 35 U.S.C. § 156(d)(5)(B).

Patent law permits patent holders to apply for additional, “subsequent,” Extensions. On that front, the statute provides that

[t]he owner of record of a patent, or its agent, for which an interim extension has been granted under subparagraph (B), may apply for not more than 4 subsequent interim extensions under this paragraph, except that, in the case of a patent subject to subsection (g)(6)(C), the owner of record of the patent, or its agent, may apply for only 1 subsequent interim extension under this paragraph. Each such subsequent application shall be made during the period beginning 60 days before, and ending 80 days before, the expiration of the preceding interim extension.

35 U.S.C. § 156(d)(5)(C) (emphasis added). It is this statute, particularly the emphasized language, which is relevant here.

C. Factual Background

i. The '759 Patent

On August 4, 1992, the USPTO issued U.S. Patent No. 5,135,759 (the “'759 Patent”) to the United States Department of Agriculture (“USDA”). (Plaintiffs Memorandum in Support (“P. Mem.”) [Dkt. 14] at 3.) The '759 Patent is entitled a “Method to Preselect the Sex of Offspring” and claimed a method of preselecting the sex of offspring by sorting sperm into X and Y chromosome bearing sperm. (Defendants’ Memorandum in Support (“D. Mem.”) [Dkt. 16] at 7.)

The USDA and GIVF entered into a private agreement under which the USDA granted GIVF an exclusive license to obtain regulatory approval for products created under the '759 Patent and to market any such products in the United States. (P. Mem. at 3.) GIVF has applied to the FDA for approval of products under the '759 Patent and has commenced clinical *501 studies. Id. GIVF has not yet received FDA approval. Id.

ii. The 2009 Extension

The '759 Patent was set to expire on August 4, 2009. Id. Because GIVF had not received FDA approval, the USDA timely filed, on June 5, 2009, an application with the USPTO for a first Extension. (D. Mem. at 7.) On July 28, 2009, the USPTO granted the first Extension, thereby extending the term of the '759 Patent for one year, to August 4, 2010. Id. The order granting the Extension was published in the Federal Register on August 4, 2009. Id.

iii. The 2010 Extension

As of July 2010, the GIVF’s FDA application was still pending. (P. Mem. at 4.) With the '759 Patent set to expire on August 4, 2010, the USDA filed a request for a second Extension with the USPTO on July 27, 2010. Id.

Under 35 U.S.C. § 156(d)(5)(C), however, the request for the second Extension was due on July 6, 2010, so the USDA’s application was untimely. Id. GIVF was responsible for drafting the second Extension application and engaged counsel to do so. (D. Mem. at 8.) “On or about” July 19, 2010, GIVF’s counsel discovered that the application was due on July 6. (P. Mem. at 4.)

GIVF’s counsel used a computer program to track patent-filing dates, and the program did not provide a reminder that the application for the second Extension was due. (D. Mem. at 8.) The program’s failure was not a malfunction, however; the program was not capable of tracking filing dates for Extension applications, though GIVF’s counsel was unaware that the program lacked this capability. Id.

Along with its July 27, 2010 application for a second Extension, the USDA petitioned the USPTO, pursuant to 37 C.F.R §§ 1.182

Free access — add to your briefcase to read the full text and ask questions with AI

Related

French v. Edwards
80 U.S. 506 (Supreme Court, 1872)
Camp v. Pitts
411 U.S. 138 (Supreme Court, 1973)
Zipes v. Trans World Airlines, Inc.
455 U.S. 385 (Supreme Court, 1982)
Russello v. United States
464 U.S. 16 (Supreme Court, 1983)
Brock v. Pierce County
476 U.S. 253 (Supreme Court, 1986)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
United States v. Montalvo-Murillo
495 U.S. 711 (Supreme Court, 1990)
Connecticut National Bank v. Germain
503 U.S. 249 (Supreme Court, 1992)
Smith v. United States
508 U.S. 223 (Supreme Court, 1993)
United States v. Granderson
511 U.S. 39 (Supreme Court, 1994)
Hughes Aircraft Co. v. Jacobson
525 U.S. 432 (Supreme Court, 1999)
TRW Inc. v. Andrews
534 U.S. 19 (Supreme Court, 2001)
National Railroad Passenger Corporation v. Morgan
536 U.S. 101 (Supreme Court, 2002)
BedRoc Limited, LLC v. United States
541 U.S. 176 (Supreme Court, 2004)
Amer Bioscience Inc v. Thompson, Tommy G.
269 F.3d 1077 (D.C. Circuit, 2001)
Merck & Co. v. Hi-Tech Pharmacal Co.
482 F.3d 1317 (Federal Circuit, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
801 F. Supp. 2d 497, 100 U.S.P.Q. 2d (BNA) 1114, 2011 U.S. Dist. LEXIS 79287, 2011 WL 2971982, Counsel Stack Legal Research, https://law.counselstack.com/opinion/genetics-ivf-institute-v-kappos-vaed-2011.